view in publisher's site

Sarcopenia as a Determinant of Chemotherapy Toxicity and Time to Tumor Progression in Metastatic Breast Cancer Patients Receiving Capecitabine Treatment

Clin Cancer Res. 2009 Apr 15;15(8):2920-6. doi: 10.1158/1078-0432.CCR-08-2242. Epub 2009 Apr 7.Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment.Prado CM1, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M, Tonkin K, Mackey JR, Koski S, Pituskin E, Sawyer MB.Author information1Agricultural, Food and Nutritional Science, University of Alberta, Edmonton, Alberta, Canada.AbstractPURPOSE: Body composition has emerged as an important prognostic factor in cancer patients. Severe depletion of skeletal muscle (sarcopenia) and, hence, of overall lean body mass may represent an occult condition in individuals with normal or even high body weight. Sarcopenia has been associated with poor performance status, 5-fluorouracil toxicity, and shortened survival in cancer patients. Here, we prospectively studied patients with metastatic breast cancer receiving capecitabine treatment in order to determine if sarcopenia was associated with a higher incidence of toxicity and a shorter time to tumor progression (TTP).EXPERIMENTAL DESIGN: Fifty-five women with metastatic breast cancer resistant to anthracycline and/or taxane treatment were included. Skeletal muscle cross-sectional area at the third lumbar vertebra was measured by computerized tomography, and sarcopenia was defined using a previously published cutoff point. Toxicity was assessed after cycle 1 of treatment, and TTP was determined prospectively.RESULTS: Approximately 25% of patients were classified as sarcopenic, and this feature was seen in normal weight, overweight, and obese individuals. Toxicity was present in 50% of sarcopenic patients, compared with only 20% of nonsarcopenic patients (P = 0.03), and TTP was shorter in sarcopenic patients (101.4 days; confidence interval, 59.8-142.9) versus nonsarcopenic patients (173.3 days; confidence interval, 126.1-220.5; P = 0.05).CONCLUSION: Sarcopenia is a significant predictor of toxicity and TTP in metastatic breast cancer patients treated with capecitabine. Our results raise the potential use of body composition assessment to predict toxicity and individualize chemotherapy dosing.PMID: 19351764 DOI: 10.1158/1078-0432.CCR-08-2242 [Indexed for MEDLINE] Free full textSharePublication type, MeSH terms, SubstancesPublication typeResearch Support, Non-U.S. Gov'tMeSH termsAdultAgedAged, 80 and overAntimetabolites, Antineoplastic/adverse effects*Antimetabolites, Antineoplastic/therapeutic useBody Composition/drug effectsBody Composition/physiologyBody Mass IndexBreast Neoplasms/drug therapy*Breast Neoplasms/pathology*CapecitabineDeoxycytidine/adverse effectsDeoxycytidine/analogs & derivatives*Deoxycytidine/therapeutic useFemaleFluorouracil/adverse effectsFluorouracil/analogs & derivatives*Fluorouracil/therapeutic useHumansMiddle AgedMuscle, Skeletal/drug effects*Muscular Diseases/chemically induced*Neoplasm MetastasisProspective StudiesSubstancesAntimetabolites, AntineoplasticDeoxycytidineCapecitabineFluorouracilLinkOut - more resourcesFull Text SourcesHighWireMedicalClinicalTrials.govMetastatic cancer - Genetic AllianceBreast Cancer - Genetic AllianceMuscle Disorders - MedlinePlus Health InformationBreast Cancer - MedlinePlus Health InformationMiscellaneousFLUOROURACIL - Hazardous Substances Data BankCAPECITABINE - Hazardous Substances Data Bank

شیمی‌درمانی به عنوان بخشی از شیمی‌درمانی و زمان به Tumor تومور در سرطان سینه بیماران مبتلا به سرطان پستان - بیماران مبتلا به سرطان پستان - بیماران مبتلا به سرطان پستان -

ترجمه شده با

سفارش ترجمه مقاله و کتاب - شروع کنید

با استفاده از افزونه دانلود فایرفاکس چکیده مقالات به صورت خودکار تشخیص داده شده و دکمه دانلود فری‌پیپر در صفحه چکیده نمایش داده می شود.